t Italian presence (trading +0.89%) • Astrazeneca announces +ve Phase III results for 2 drugs & safety extension for Neloxegol (trading -0.28%) • Bovis Homes IMS inline, confirms guidance & remains on track to deliver strong revenues (trading +0.29%) EFTA00401614 • Taylor Wimpey IMS inline, market stable,